All Paul McKenzie articles
-
News
CSL opens $1bn Australian vaccine and antivenom manufacturing facility
The Melbourne site adds Australia to a select group of nations with advanced cell-based influenza vaccine capabilities.
-
News
CSL to slash headcount by 15% and spinout its CSL Seqirus vaccines business
The Australian biotech's new operating model will also see medical and commercial functions at its CSL Behring and CSL Vifor units combined.